Analyst Rating Update on Medivation (MDVN)

Medivation (MDVN) : The consensus on Medivation (MDVN) based on 13 analyst recommendation on the company stock is 1.62, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 5 which endorses a Strong Sell on the stock. However, 9 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Medivation (MDVN) : 14 Wall Street analysts covering Medivation (MDVN) believe that the average level the stock could reach for the short term is $63.5. The maximum price target given is $76 and the minimum target for short term is around $40, hence the standard deviation is calculated at $10.04.

For the current week, the company shares have a recommendation consensus of Buy.


Medivation (NASDAQ:MDVN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $63.62 and $63.26 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $64.12. The buying momentum continued till the end and the stock did not give up its gains. It closed at $64.08, notching a gain of 0.79% for the day. The total traded volume was 1,004,580 . The stock had closed at $63.58 on the previous day.

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *